You are here

Generic Version of Tambocor Gains FDA Approval

PRINCETON, N.J., March 31 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to market Flecainide Acetate Tablets USP, in 50 mg, 100 mg, and 150 mg strengths. The Division of Bioequivalence has determined Ranbaxy's Flecainide Acetate Tablets USP, 50 mg, 100 mg, and 150 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug Tambocor(TM) Tablets, 50 mg, 100 mg, and 150 mg, respectively, of 3M Pharmaceuticals, Inc.

In patients without structural heart disease, Tambocor(TM) is indicated for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms, paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Tambocor(TM) is also indicated for the prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening. In 2002, the total sales of Flecainide Acetate Tablets totaled $105.6 million (IMS - MAT, Dec. 2002).

Product is expected to be available through wholesalers and other distribution outlets to dispensing pharmacies throughout the United States. According to Mr. Dipak Chattaraj, President of Ranbaxy Pharmaceuticals Inc., "With the addition of Flecainide Acetate Tablets, Ranbaxy's generic product line is expanding to meet the clinical needs of the U.S. Healthcare System that includes prescribers, patients and health plans with a generic alternative for this cardiovascular product. Flecainide will be manufactured in the U.S. at Ohm Laboratories, our facility located in North Brunswick, NJ."

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission